Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK 732462
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
**GSK 732462**, also designated **SB732462** and described in publications as **F4/AS01B**, was GSK's investigational therapeutic HIV-1 vaccine for people already infected with HIV-1. It combined the recombinant F4 fusion antigen, incorporating HIV-1 clade B p17, p24, reverse transcriptase, and Nef antigens, with GSK's AS01B adjuvant system. The vaccine was designed to amplify HIV-specific cellular immunity, particularly polyfunctional CD4-positive T-cell responses, with the intended goal of improving control of viral replication and potentially delaying antiretroviral-therapy initiation. Phase I and Phase II studies found it generally safe and immunogenic, but the Phase IIb trial did not demonstrate viral-load efficacy in ART-naive adults with HIV-1 infection. ([clinicaltrialsregister.eu](https://www.clinicaltrialsregister.eu/ctr-search/rest/download/result/attachment/2010-021356-26/1/1375))
- Other names
- F4/AS01B
02
Targets
Nef (HIV-1 Nef)Human immunodeficiency virus type 1 reverse transcriptaseTLR4 (Toll-like receptor 4)p24 (HIV-1 capsid protein p24)p17 (HIV-1 matrix protein p17)Nef (Human immunodeficiency virus type 1 negative factor)
Beyond the preview
Go deeper on GSK 732462.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK 732462.